Chronic Pulmonary Hypertension Treatment Market Report 2026

The chronic pulmonary hypertension treatment market size has grown strongly in recent years. It will grow from $7.19 billion in 2025 to $7.59 billion in 2026 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular and respiratory disorders, improved awareness of pulmonary hypertension, wider availability of oral PDE-5 inhibitors, expansion of specialty treatment centers, increased use of diagnostic imaging.

The chronic pulmonary hypertension treatment market size is expected to see strong growth in the next few years. It will grow to $9.34 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to increasing approvals of novel PH drugs, rising investment in rare disease therapies, growing adoption of inhalational drug delivery, expansion of telemedicine-based disease management, increasing focus on patient-centric care models. Major trends in the forecast period include increasing adoption of targeted pulmonary hypertension drugs, rising use of combination therapy regimens, growing focus on early diagnosis and disease monitoring, expansion of home-based oxygen and supportive therapies, enhanced emphasis on personalized treatment protocols.

The high burden of cardiovascular diseases is expected to drive the growth of the chronic pulmonary hypertension treatment market in the coming years. Cardiovascular diseases include a range of disorders affecting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. The increasing burden of these conditions is linked to risk factors including unhealthy diets, lack of physical activity, tobacco use, excessive alcohol intake, obesity, hypertension, diabetes, and aging populations. Treatment for chronic pulmonary hypertension supports cardiovascular health by reducing pulmonary artery pressure, improving heart function, and lowering the risk of heart failure and related complications. For example, in August 2025, according to the National Institutes of Health, a US-based government agency, cardiovascular disease prevalence is projected to increase by 90% between 2025 and 2050, mortality by 73%, and disability-adjusted life years by 55%, with deaths rising from 20.5 million to 35.6 million. Therefore, the high burden of cardiovascular diseases is contributing to the growth of the chronic pulmonary hypertension treatment market.

Major companies operating in the chronic pulmonary hypertension treatment market are focusing on innovative approaches such as subcutaneous injections to improve patient adherence, enhance convenience, and deliver more targeted therapies. Subcutaneous injection allows for continuous delivery of medication beneath the skin, helping to reduce pulmonary artery pressure and improve blood flow in patients with pulmonary hypertension. For instance, in March 2024, Merck & Co. Inc., a US-based pharmaceutical company, announced that the US Food and Drug Administration approved Winrevair (sotatercept-csrk), representing a major advancement in the treatment of pulmonary arterial hypertension. Clinical trial data showed that Winrevair improved WHO functional class in 29% of treated patients, compared to 14% in the placebo group, resulting in an overall improvement in quality of life.

In October 2024, Liquidia Corporation, a US-based biopharmaceutical company, entered into a partnership with Pharmosa Biopharm to expand the development and commercialization of L606. Through this collaboration, Liquidia Corporation and Pharmosa Biopharm aim to advance an inhaled treprostinil therapy to improve treatment options for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Pharmosa Biopharm is a Taiwan-based biotechnology company specializing in the research, development, and commercialization of pharmaceutical products and medical devices.

Major companies operating in the chronic pulmonary hypertension treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi SA, AstraZeneca PLC, Novartis AG, GSK (GlaxoSmithKline), Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Boehringer Ingelheim, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Insmed, Cereno Scientific, Roivant Sciences, LGM Pharma, Liquidia Technologies.

North America was the largest region in the chronic pulmonary hypertension treatment market in 2025. The regions covered in the chronic pulmonary hypertension treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chronic pulmonary hypertension treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the chronic pulmonary hypertension treatment market by increasing costs of imported active ingredients, specialized drug delivery systems, and diagnostic equipment used in advanced PH therapies. North America and Europe are most impacted due to reliance on international pharmaceutical manufacturing networks, while Asia-Pacific faces higher production costs for export-oriented medications. These tariffs are contributing to higher treatment costs and reimbursement pressures. However, they are also driving local pharmaceutical manufacturing, regional clinical research investments, and diversification of supply chains to enhance long-term treatment accessibility.

The chronic pulmonary hypertension treatment market research report is one of a series of new reports that provides chronic pulmonary hypertension treatment market statistics, including chronic pulmonary hypertension treatment industry global market size, regional shares, competitors with a chronic pulmonary hypertension treatment market share, detailed chronic pulmonary hypertension treatment market segments, market trends and opportunities, and any further data you may need to thrive in the chronic pulmonary hypertension treatment industry. This chronic pulmonary hypertension treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Chronic pulmonary hypertension (PH) treatment involves the management of elevated blood pressure in the lungs to enhance heart function and improve quality of life. It includes the use of medications to lower pulmonary pressure, oxygen therapy, and diuretics to relieve symptoms. More advanced approaches include pulmonary rehabilitation, lifestyle changes, and medical procedures when required. In severe cases, surgical interventions may also be considered.

The primary drug types used in chronic pulmonary hypertension include endothelin receptor antagonists (ERAs), phosphodiesterase (PDE-5) inhibitors, prostacyclin analogs, and soluble guanylate cyclase (SGC) stimulators. ERAs are medications that block the effects of endothelin to manage pulmonary hypertension and improve patient outcomes. These drugs are administered through multiple routes such as oral, intravenous, subcutaneous, and inhalational, and are distributed via hospital pharmacies, retail pharmacies, and online pharmacies.

The chronic pulmonary hypertension treatment market consists of revenues earned by entities by providing services such as pharmacological treatment services, cardiopulmonary rehabilitation, telemedicine and remote patient monitoring, oxygen therapy, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic pulmonary hypertension treatment market also includes sales of calcium channel blockers, pulmonary artery pressure monitoring systems, inhalation devices, and oxygen therapy equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.